Ann: Appendix 4C and Quarterly Update, page-62

Ongoing Trials:
"Dogs that have completed the 28 day trial have access to MPL tablets to continue treatment on the long-term maintenance dose. Vets are continuing to administer a low dose of MPL as a first line therapy to new dogs under a supplementary clinical study."

Well that's very positive, but to run with a cranky theme today
1/ Why wasn't I informed of this supplemental clinical study BEFORE it started !
2/ PharmAust still managed to word this without clearly stating that existing dogs are on long-term maintenance doses - all very appealing to the tea leaf readers of Australia but I believe this is a public company ....

Other have come to this conclusion before me, but I finally agree that PharmAust doesn't have the mixture anywhere near right between the slow, wise and stubborn, versus... the fast, driven and stubborn. We're in need of a clear separation between a mentoring figurehead and a fast, hard driving CEO. The current setup is suboptimal, pedestrian and detrimental imo.

Happily, I do believe we're sitting on a volcano ... potentially a wonder drug and possibly a new class of wonder drugs ... That a happy ending is in store for us despite shall we say, inertia.

But oh, for a market presence, for a publicist given the authority and freedom to drive PharmAust 24/7

Yes NZ I admit it ... I've become you